Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 6/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.36 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.36 |
| ▸ | KARS1 | Q15046 | 3/20 | 0.35 |
| ▸ | FAAH | O00519 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | WNT1 | P04628 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776014 | 0.89 | GRM5 (0.40) | GSK3BDYRK1AABL1KCNH2HRH3 | |
| SCHEMBL16775904 | 0.84 | GRM5 (0.42) | KARS1FAAHMAPTRAB9AKDM4E | |
| SCHEMBL16776198 | 0.84 | GRM5 (0.39) | GSK3BDYRK1AABL1KCNH2HRH3 | |
| SCHEMBL16776465 | 0.84 | NPC1 (0.36) | GSK3BDYRK1AKARS1FAAHWNT1 | |
| SCHEMBL19365751 | 0.83 | GSK3B (0.38) | GSK3BDYRK1APORCNFAAHMAPT | |
| SCHEMBL16776032 | 0.83 | KCNH2 (0.41) | GSK3BFAAHMAPTABL1KCNH2 | |
| SCHEMBL16775991 | 0.83 | THRB (0.39) | KARS1HDAC2 | |
| SCHEMBL16776017 | 0.83 | GSK3B (0.38) | GSK3BDYRK1AMAPTABL1KCNH2 | |
| SCHEMBL16776240 | 0.83 | WNT1 (0.35) | GSK3BDYRK1AKARS1MAPTWNT1 | |
| SCHEMBL16776055 | 0.82 | KARS1 (0.49) | GSK3BDYRK1AKARS1FAAHABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GSK3B 1728/4885DYRK1A 2623/4885PORCN 3797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.